利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.021 秒)

    Treatment for toxoplasmosis with a composition comprising a macrolide antibiotic and a spiropiperidyl derivative of rifamycin S
    3.
    发明授权
    Treatment for toxoplasmosis with a composition comprising a macrolide antibiotic and a spiropiperidyl derivative of rifamycin S 失效
    用包含大环内酯类抗生素和利福霉素S的螺哌啶衍生物的组合物治疗弓形虫病

    公开(公告)号：US5648345A

    公开(公告)日：1997-07-15

    申请号：US474998

    申请日：1995-06-07

    申请人： Jack S. Remington ,  Fausto G. Araujo

    发明人： Jack S. Remington ,  Fausto G. Araujo

    IPC分类号： C07D498/18 ,  A61K31/395 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/438 ,  A61K31/445 ,  A61P33/02 ,  A61P33/10 ,  A61K31/33 ,  A61K31/55

    CPC分类号： A61K31/435 ,  A61K31/4353 ,  A61K31/438 ,  A61K31/445 ,  A61K31/70

    摘要： A method of reducing the severity of toxoplasmosis resulring from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.

    摘要翻译： 一种通过在感染后或暴露于感染之前对需要这种治疗的患者施用治疗有效量的化合物来降低弓形体感染患者弓形虫病的严重程度的方法，所述化合物是作为 利福霉素S，其中所述衍生物包含咪唑环，所述咪唑环包括在利福霉素环的3和4位上的碳，咪唑环的第2位的碳也是哌啶环体系的第4位的环碳，从而形成一个哌啶基 环系统，所述哌啶基环系统任选地在哌啶的氮上包含低级烃取代基。

    Immunoassay for detecting immunoglobulins and test kit
    5.
    发明授权
    Immunoassay for detecting immunoglobulins and test kit 失效
    用于检测免疫球蛋白和测试试剂盒的免疫测定

    公开(公告)号：US4612281A

    公开(公告)日：1986-09-16

    申请号：US439433

    申请日：1982-11-05

    申请人： Georges Desmonts ,  Jack S. Remington

    发明人： Georges Desmonts ,  Jack S. Remington

    IPC分类号： G01N33/569 ,  G01N33/68 ,  G01N33/53

    CPC分类号： G01N33/6854 ,  G01N33/569 ,  Y10S435/81 ,  Y10S435/975 ,  Y10S436/805 ,  Y10S436/808 ,  Y10S436/811

    摘要： An immunoassay for detecting disease associated Ig, such as IgM associated with acute forms of Toxoplasma gondii infection. Wells of microtiter plates are first coated with an antibody against the Ig to be detected and the test sample, e.g. serum, is then added and incubated. After removal of non-adsorbed materials from the wells, an insoluble visible form of the cognate antigen to the Ig, such as antigen fixed to latex particles, is added. If no such Ig is present in the sample, the antigen will appear as a smooth button on the bottom of the well; whereas if such Ig is present in significant quantity, the antigen will be captured by adsorbed antiIg-Ig complexes and distributed on the wall of the well according to the distribution of the antiIg-Ig complex thereon.

    摘要翻译： 用于检测疾病相关Ig的免疫测定，例如与急性形式弓形体感染相关的IgM。 首先用针对待检测的Ig的抗体包被微量滴定板的孔，并将测试样品，例如， 血清，然后加入并孵育。 在从孔中除去未吸附的物质之后，加入到Ig的同源抗原的不溶性可见形式，例如固定在胶乳颗粒上的抗原。 如果样品中不存在这样的Ig，则抗原将在孔的底部显示为平滑按钮; 而如果Ig大量存在，则抗原将被吸附的抗Igg复合物捕获，并根据其上的抗Ig-Ig复合物的分布分布在孔壁上。

    Treatment for toxoplasmosis with a composition comprising a lincosamide and a spiropiperidyl derivative of rifamycik S
    7.
    发明授权
    Treatment for toxoplasmosis with a composition comprising a lincosamide and a spiropiperidyl derivative of rifamycik S 失效
    用含有林可酰胺和利福霉素S的螺哌啶衍生物的组合物治疗弓形虫病

    公开(公告)号：US5665707A

    公开(公告)日：1997-09-09

    申请号：US487721

    申请日：1995-06-07

    申请人： Jack S. Remington ,  Fausto G. Araujo

    发明人： Jack S. Remington ,  Fausto G. Araujo

    IPC分类号： C07D498/18 ,  A61K31/395 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/438 ,  A61K31/445 ,  A61P33/02 ,  A61P33/10 ,  A61K31/70 ,  A61K31/33

    CPC分类号： A61K31/435 ,  A61K31/4353 ,  A61K31/438 ,  A61K31/445 ,  A61K31/70

    摘要： A method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.

    摘要翻译： 一种降低由弓形虫病人感染引起的弓形虫病的严重性的方法，其通过在感染后或暴露于感染之前向需要这种治疗的患者施用治疗有效量的化合物，所述化合物是作为 利福霉素S，其中所述衍生物包含咪唑环，所述咪唑环包括在利福霉素环的3和4位上的碳，咪唑环的第2位的碳也是哌啶环体系的第4位的环碳，从而形成一个哌啶基 环系统，所述哌啶基环系统任选地在哌啶的氮上包含低级烃取代基。

    Treatment for toxoplasmosis with a composition comprising a sulfonamide and a spiropiperidyl derivative of rifamycin S.
    8.
    发明授权
    Treatment for toxoplasmosis with a composition comprising a sulfonamide and a spiropiperidyl derivative of rifamycin S. 失效
    用包含磺酰胺和利福霉素S的spiropiperidyl衍生物的组合物治疗弓形虫病

    公开(公告)号：US5650405A

    公开(公告)日：1997-07-22

    申请号：US481741

    申请日：1995-06-07

    申请人： Jack S. Remington ,  Fausto G. Araujo

    发明人： Jack S. Remington ,  Fausto G. Araujo

    IPC分类号： C07D498/18 ,  A61K31/395 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/438 ,  A61K31/445 ,  A61P33/02 ,  A61P33/10 ,  A61K31/33 ,  A61K31/42 ,  A61K31/425 ,  A61K31/505

    CPC分类号： A61K31/435 ,  A61K31/4353 ,  A61K31/438 ,  A61K31/445 ,  A61K31/70

    摘要： A method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.

    摘要翻译： 一种降低由弓形虫病人感染引起的弓形虫病的严重性的方法，其通过在感染后或暴露于感染之前向需要这种治疗的患者施用治疗有效量的化合物，所述化合物是作为 利福霉素S，其中所述衍生物包含咪唑环，所述咪唑环包括在利福霉素环的3和4位上的碳，咪唑环的第2位的碳也是哌啶环体系的第4位的环碳，从而形成一个哌啶基 环系统，所述哌啶基环系统任选地在哌啶的氮上包含低级烃取代基。

    Treatment for toxoplasmosis
    9.
    发明授权
    Treatment for toxoplasmosis 失效
    治疗弓形虫病

    公开(公告)号：US5529994A

    公开(公告)日：1996-06-25

    申请号：US203539

    申请日：1994-02-28

    申请人： Jack S. Remington ,  Fausto G. Araujo

    发明人： Jack S. Remington ,  Fausto G. Araujo

    IPC分类号： A61K31/435 ,  A61K31/445 ,  A61K31/33 ,  A61K31/70

    CPC分类号： A61K31/435 ,  A61K31/445 ,  A61K31/70

    摘要： A method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.

    摘要翻译： 一种降低由弓形虫病人感染引起的弓形虫病的严重性的方法，其通过在感染后或暴露于感染之前向需要这种治疗的患者施用治疗有效量的化合物，所述化合物是作为 利福霉素S，其中所述衍生物包含咪唑环，所述咪唑环包括在利福霉素环的3和4位上的碳，咪唑环的第2位的碳也是哌啶环体系的第4位的环碳，从而形成一个哌啶基 环系统，所述哌啶基环系统任选地在哌啶的氮上包含低级烃取代基。